title: Insulin and insulin-like growth factor signaling increases proliferation and hyperplasia of the ovarian surface epithelium and decreases follicular integrity through upregulation of the PI3-kinase pathway.
abstract: BACKGROUND
  The ovarian surface epithelium responds to cytokines and hormonal cues to initiate proliferation and migration following ovulation. Although insulin and IGF are potent proliferative factors for the ovarian surface epithelium and IGF is required for follicle development, increased insulin and IGF activity are correlated with at least two gynecologic conditions: polycystic ovary syndrome and epithelial ovarian cancer. Although insulin and IGF are often components of in vitro culture media, little is known about the effects that these growth factors may have on the ovarian surface epithelium morphology or how signaling in the ovarian surface may affect follicular health and development.
  
  
  METHODS
  Ovaries from CD1 mice were cultured in alginate hydrogels in the presence or absence of 5 μg/ml insulin or IGF-I, as well as small molecule inhibitors of IR/IGF1R, PI 3-kinase signaling, or MAPK signaling. Tissues were analyzed by immunohistochemistry for expression of cytokeratin 8 to mark the ovarian surface epithelium, Müllerian inhibiting substance to mark secondary follicles, and BrdU incorporation to assess proliferation. Changes in gene expression in the ovarian surface epithelium in response to insulin or IGF-I were analyzed by transcription array. Extracellular matrix organization was evaluated by expression and localization of collagen IV.
  
  
  RESULTS
  Culture of ovarian organoids with insulin or IGF-I resulted in formation of hyperplastic OSE approximately 4-6 cell layers thick with a high rate of proliferation, as well as decreased MIS expression in secondary follicles. Inhibition of the MAPK pathway restored MIS expression reduced by insulin but only partially restored normal OSE growth and morphology. Inhibition of the PI 3-kinase pathway restored MIS expression reduced by IGF-I and restored OSE growth to a single cell layer. Insulin and IGF-I altered organization of collagen IV, which was restored by inhibition of PI 3-kinase signaling.
  
  
  CONCLUSIONS
  While insulin and IGF are often required for propagation of primary cells, these cytokines may act as potent mitogens to disrupt cell growth, resulting in formation of hyperplastic OSE and decreased follicular integrity as measured by MIS expression and collagen deposition. This may be due partly to altered collagen IV deposition and organization in the ovary in response to insulin and IGF signaling mediated by PI 3-kinase.
authors: Department of Medicinal Chemistry and Pharmacognosy, University of Illinois, 900 S, Ashland Room 3202, Chicago, IL, 60607, USA. joannab@uic.edu.
authors: Shelby M
authors: SM
authors: King
authors: Dimple A
authors: DA
authors: Modi
authors: Sharon L
authors: SL
authors: Eddie
authors: Joanna E
authors: JE
authors: Burdette
references: Endocr Rev. 1992 Nov;13(4):641-69
references: 1281087
references: Endocrinology. 1997 Apr;138(4):1427-33
references: 9075698
references: Nat Rev Cancer. 2008 Dec;8(12):915-28
references: 19029956
references: Exp Cell Res. 1998 Feb 1;238(2):439-49
references: 9473353
references: J Assist Reprod Genet. 2011 Jan;28(1):3-6
references: 20872066
references: Int J Cancer. 2001 Feb 1;91(3):309-15
references: 11169952
references: Lab Invest. 1994 Oct;71(4):510-8
references: 7967506
references: Int J Gynecol Cancer. 2006 Mar-Apr;16(2):501-6
references: 16681718
references: Anim Reprod Sci. 2009 Sep;114(4):443-8
references: 19042098
references: Histochem Cell Biol. 2006 Nov;126(5):583-92
references: 16758163
references: Endocr Rev. 2009 Oct;30(6):624-712
references: 19776209
references: BMC Cancer. 2010 May 26;10:237
references: 20504346
references: Biol Cell. 2009 Jan;101(1):13-29
references: 19055486
references: Cancer Sci. 2003 Nov;94(11):953-9
references: 14611671
references: Carcinogenesis. 2000 Apr;21(4):585-91
references: 10753190
references: Mol Reprod Dev. 2001 Jun;59(2):178-85
references: 11389552
references: Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R587-92
references: 19439618
references: Mol Cell. 2001 May;7(5):937-47
references: 11389841
references: Am J Hypertens. 2012 Dec;25(12):1271-8
references: 22895451
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Biol Reprod. 1991 Apr;44(4):717-24
references: 1710511
references: Lancet. 1971 Jul 17;2(7716):163
references: 4104488
references: Cancer Lett. 2012 Dec 30;326(2):191-8
references: 22922215
references: Gynecol Oncol. 1994 May;53(2):196-201
references: 8188079
references: Endocr Rev. 2001 Apr;22(2):255-88
references: 11294827
references: J Obstet Gynaecol Res. 2007 Feb;33(1):3-16
references: 17212660
references: Endocrinology. 2009 Aug;150(8):3921-6
references: 19423762
references: Endocr Relat Cancer. 2011 Sep 20;18(5):627-42
references: 21813729
references: J Vis Exp. 2011 Jun 20;(52):
references: 21712801
references: Macromol Biosci. 2006 Aug 7;6(8):623-33
references: 16881042
references: Hormones (Athens). 2006 Jan-Mar;5(1):17-34
references: 16728382
references: Biochem J. 1993 Mar 1;290 ( Pt 2):419-26
references: 8452530
references: Gynecol Oncol. 2005 Feb;96(2):355-61
references: 15661221
references: Lab Invest. 2004 Jul;84(7):923-31
references: 15077121
references: Biomaterials. 2007 Oct;28(30):4439-48
references: 17643486
references: Hum Reprod. 2011 Sep;26(9):2473-85
references: 21669966
references: Proc Nutr Soc. 2001 Feb;60(1):91-106
references: 11310428
references: Domest Anim Endocrinol. 1995 Jul;12(3):223-45
references: 7587167
references: J Anim Sci. 1993 Nov;71(11):3033-42
references: 8270525
references: Nature. 1995 Dec 21-28;378(6559):785-9
references: 8524413
references: Arch Physiol Biochem. 2009 May;115(2):72-85
references: 19485703
references: Biol Reprod. 2012 Oct 04;87(4):80
references: 22914315
references: Obstet Gynecol. 1996 Oct;88(4 Pt 1):554-9
references: 8841217
references: Endocrinology. 2010 Apr;151(4):1863-71
references: 20176725
references: Arch Gynecol Obstet. 2006 Jul;274(4):187-97
references: 16685527
references: Cancer Res. 2009 Apr 1;69(7):2996-3003
references: 19318572
references: Endocr Rev. 1984 Spring;5(2):356-69
references: 6376081